News Archive
Our Products are IVDR-Certified!
We have successfully obtained our certification under the new In Vitro Diagnostic Regulation (IVDR; 2017/746)! The first batch of flagship products are already available on the market under the new IVDR, well in advance of the transition period deadline.
Improved – ME033 TNDM – Featuring Updated Target and Reference Probes
ME033 TNDM just received a major update with version B1 featuring the addition of five new target probes and the replacement of seven target probes as well as all ten reference probes, further refining the performance of the probemix in order to detect the majority of TNDM cases.
MLPA in Challenging Glioblastoma Cases
A brief research report published in Pathology & Oncology Research by researchers from the Czech Republic highlighted the inherent challenges of characterising glioblastoma by comparing multiple widely used methodologies, including MLPA.
Improved: P062 LDLR – Featuring a New Target Probe for Exon 18 of LDLR
P062 LDLR just received a major update, with the recently released E1 version featuring a new target probe for exon 18 of the LDLR gene.
New: P498 CSTB
P498 CSTB is a new assay developed to specifically detect deletions or duplications in the CSTB gene.
New: P477 Head and Neck Carcinoma
New probemix: P477 Head and neck carcinoma targets the most frequently altered regions in HNSCCs and includes 36 probes for the CUL3, PIK3CA, SOX2, FAT1, KIAA0825, EGFR, SNAI2, NFIB, CCND1, FADD, TGIF1 and BCL2L1 genes.
A Year in Review – 2024
As we look back on 2024, we are excited to share some of the year’s highlights with you!
Upcoming Changes to MLPA Product Descriptions
In the coming years we will update product descriptions for SALSA® MLPA® products that are for in vitro diagnostic (IVD) use to a new structure and layout.
Implementation of Nationwide Newborn Screening for Spinal Muscular Atrophy in Serbia
Researchers from the University of Belgrade succeeded in making state-wide newborn screening become a reality through a stepwise plan that included a laboratory validation step, a feasibility study on a smaller cohort of newborns, and finally the transition to a national program.
Identification of a Distinct Subclass of Head and Neck Cancers
Researchers from the Amsterdam University Medical Centre recently published a study on a distinct subclass of head and neck cancers in collaboration with MRC Holland scientists.